美国感染病学会关于产AmpC β-内酰胺酶肠杆菌目、耐碳青霉烯鲍曼不动杆菌和嗜麦芽窄食单胞菌感染治疗的指南
美国感染病学会(IDSA)发布针对产AmpC β-内酰胺酶肠杆菌目(AmpC-E)、耐碳青霉烯鲍曼不动杆菌(CRAB)和嗜麦芽窄食单胞菌感染的治疗指南。由6名感染病专家组成的小组基于临床经验、专家意见和文献综述提出「建议方案」,适用于成人和儿童,并推荐感染病专科会诊。文件截至2021年9月17日,将每年更新。
要点
- 本指南针对AmpC-E、CRAB和嗜麦芽窄食单胞菌感染提供「建议方案」,基于临床经验、专家意见和文献综述。
- 建议适用于成人和儿童,前提是已鉴定病原体且已知药敏结果。
- 推荐对耐药菌感染的治疗咨询感染病专科医生。
核心结论
- 针对AmpC-E、CRAB和嗜麦芽窄食单胞菌感染的最佳治疗已发表数据有限,本指南以「建议方案」形式提供基于临床经验、专家意见和文献综述的指导。
研究设计与样本
- 美国感染病学会(IDSA)召集6名擅长管理耐药菌感染的感染病专家组成小组,针对AmpC-E、CRAB和嗜麦芽窄食单胞菌感染的治疗提出问题,以建议方案和相应理由的形式呈现答案。
主要发现
- 与先前针对产超广谱β-内酰胺酶肠杆菌目(ESBL-E)、耐碳青霉烯肠杆菌目(CRE)和难治性耐药铜绿假单胞菌(DTR-P. aeruginosa)的指南不同,关于AmpC-E、CRAB和嗜麦芽窄食单胞菌感染最佳治疗的已发表数据有限。
关键数值与推荐
- 文件提供首选和备选治疗建议,假设已鉴定病原体且已知抗生素药敏结果。
- 文件简要讨论了经验性治疗、疗程和其他管理考虑。
- 建议适用于成人和儿童人群。
- 推荐对耐药菌感染的治疗咨询感染病专科医生。
临床怎么用
- 原文未据此给出推荐。
局限性
- 与先前指南不同,关于AmpC-E、CRAB和嗜麦芽窄食单胞菌感染最佳治疗的已发表数据有限。
- 由于国际上耐药流行病学和特定抗感染药物可及性存在差异,本文件聚焦于美国感染的治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Acinetobacter baumannii (CRAB), and Stenotrophomonas maltophilia infections. A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of AmpC-E, CRAB, and S. maltophilia infections. Answers are presented as suggested approaches and corresponding rationales. In contrast to guidance in the previous document, published data on the optimal treatment of AmpC-E, CRAB, and S. maltophilia infections are limited. As such, guidance in this document is provided as "suggested approaches" based on clinical experience, expert opinion, and a review of the available literature. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Preferred and alternative treatment suggestions are provided, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Suggestions apply for both adult and pediatric populations. The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 17 September 2021 and will be updated annually. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance-2.0/.
引用
- Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections. Clin Infect Dis. 2022. PMID: 34864936. doi:10.1093/cid/ciab1013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。